Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): Report from the SENTRY Antimicrobial Surveillance Program

Diagnostic Microbiology and Infectious Disease

Volumn 46, Issue 1, 2003, Pages 77-80

  Jones, Ronald N ^a,b   Biedenbach, Douglas J ^a   Beach, Mondell L ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFEPIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFANT; MEDICAL PRACTICE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NORTH AMERICA; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0037724174     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00015-4     Document Type: Article

References (12)

1. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States 1995-1999. MMWR. 50:2001;800-804.
2. Chen D.J., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl J Med. 341:1999;233-239.
3. Diekema D.J., Pfaller M.A., Jones R.N. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America SENTRY Antimicrobial Surveillance Program, 1997-2000. Intern J Antimicrob Agents. 20:2002;412-418.
4. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., Gradelski E., Vaera L., Bonner D.P. Antibacterial spectrum of a novel des-fluoro(6)quinolone, BMS284756. Antimicrob Agents Chemother. 44:2000;3351-3356.
5. Goldstein E.J.C., Garabedian-Ruffalo S.M. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis. 35:2002;1505-1511.
6. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvalez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32:(Suppl 2):2001;S81-S93.
7. Malbruny B., Canu A., Bozdogan B., Fantin B., Zarrouk V., Dutka-Malen S., Feger C., Leclercq R. Resistance to quinupristin/dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother. 46:2002;2200-2207.
8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - Fifth Edition: Approved standard M7-A5. 2000;NCCLS, Wayne, PA.
9. Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. M100-S12. 2002;NCCLS, Wayne, PA.
10. Rubino, C. M., Webb, C., Jones, R. N., Grasela, D. M., & Ambrose, P. G. (2002). Impact of pharmacokinetic and microbiological variability of the pharmacodynamics of gatifloxacin against S. pneumoniae in children, abstr. G-1466. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA.
11. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., Minami S., Watanabe Y., Narita H. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother. 43:1999;1077-1084.
12. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Lexau C., Reingold A., Lefkowitz L., Cieslak P.R., Cetron M., Zell E.R., Stat M., Jorgensen J.H., Schuchat A. Program of the Emerging Infections Program Network. Increasing prevalence of multiple drug resistant S. pneumoniae in the United States. New Engl J Med. 343:2000;1917-1924.